Portola Pharmaceuticals (original) (raw)

dbo:abstract

Portola Pharmaceuticals ist ein US-amerikanisches, biotechnologisches Pharmaunternehmen, das 2003 in Delaware gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen PTLA gelistet ist. Seinen Hauptsitz hat Portola in San Francisco, CA. Das Unternehmen ist spezialisiert auf die Entdeckung, Entwicklung und Vermarktung neuartiger Therapeutika aus den Bereichen Thrombose und anderen hämatologischen Erkrankungen. (de)
Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Founded and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola. (en)

dbo:fate

Acquired byAlexion Pharmaceuticals (en)

dbo:foundingYear

2003-01-01 (xsd:gYear)

dbo:industry

dbr:Pharmaceutical_company

dbo:keyPerson

dbr:Chief_Executive_Officer

dbo:location

dbr:South_San_Francisco,_California

dbo:numberOfEmployees

324 (xsd:nonNegativeInteger)

dbo:product

dbo:revenue

40130.0

dbo:type

dbr:Public_company

dbo:wikiPageID

58943905 (xsd:integer)

dbo:wikiPageLength

6270 (xsd:nonNegativeInteger)

dbo:wikiPageRevisionID

1122471398 (xsd:integer)

dbo:wikiPageWikiLink

dbp:areaServed

Worldwide (en)

dbp:fate

Acquired by Alexion Pharmaceuticals (en)

dbp:foundation

2003 (xsd:integer)

dbp:founders

Charles J. Homcy, David R. Philips (en)

dbp:industry

dbr:Pharmaceutical_company

dbp:keyPeople

Scott Garland (en)

dbp:location

South San Francisco, California, United States (en)

dbp:name

Portola Pharmaceuticals (en)

dbp:numEmployees

324 (xsd:integer)

dbp:products

dbp:revenue

40130.0

dbp:subsid

Portola Pharma UK Limited (en)

dbp:type

dbr:Public_company

dbp:wikiPageUsesTemplate

dcterms:subject

rdf:type

rdfs:comment

Portola Pharmaceuticals ist ein US-amerikanisches, biotechnologisches Pharmaunternehmen, das 2003 in Delaware gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen PTLA gelistet ist. Seinen Hauptsitz hat Portola in San Francisco, CA. Das Unternehmen ist spezialisiert auf die Entdeckung, Entwicklung und Vermarktung neuartiger Therapeutika aus den Bereichen Thrombose und anderen hämatologischen Erkrankungen. (de)
Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Founded and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola. (en)

rdfs:label

Portola Pharmaceuticals (de)
Portola Pharmaceuticals (en)

owl:sameAs

prov:wasDerivedFrom

wikipedia-en:Portola_Pharmaceuticals?oldid=1122471398&ns=0

foaf:isPrimaryTopicOf

wikipedia-en:Portola_Pharmaceuticals

foaf:name

Portola Pharmaceuticals (en)

is dbo:wikiPageDisambiguates of

dbr:Portola

is dbo:wikiPageWikiLink of

is foaf:primaryTopic of

wikipedia-en:Portola_Pharmaceuticals